FDA Expands Phytosterol Heart Health Claim In Proposed Rule
This article was originally published in The Tan Sheet
Executive Summary
FDA significantly overhauls a health claim linking phytosterols to a reduced risk of coronary heart disease, expanding the type of enriched conventional foods and forms of dietary supplements that can make the claim.
You may also be interested in...
Statin Drug Makes SPORT Of Supplements In Pharma-Funded, 28-Day Trial On Lowering LDL
Primary and secondary endpoint results in “Supplements, Placebo, or Rosuvastatin” study conducted by Cleveland Clinic include no difference, after four weeks, in total cholesterol and blood triglyceride measures between subjects receiving placebo and those using fish oil, cinnamon, garlic, turmeric, plant sterols or red yeast rice.
Pfizer Proposes Criteria To Allow Free Phytosterol CHD Reduction Claim
FDA should allow CHD reduction claims for nonesterified phytosterol supplements to that disperse efficiently from tablet form and help block cholesterol uptake, Pfizer argues in comments to the agency.
Pfizer Proposes Criteria To Allow Free Phytosterol CHD Reduction Claim
FDA should allow CHD reduction claims for nonesterified phytosterol supplements to that disperse efficiently from tablet form and help block cholesterol uptake, Pfizer argues in comments to the agency.